InMed Pharmaceuticals (NASDAQ:INM) Stock: Insider Adar1 Capital Management, Llc Buys 8,021 Shares

Posted by Mark Dietrich on Oct 17th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) major shareholder Adar1 Capital Management, Llc purchased 8,021 shares of InMed Pharmaceuticals stock in a transaction that occurred on Wednesday, October 14th. The shares were purchased at an average cost of $1.33 per share, with a total value of $10,667.93. Following the transaction, the insider directly owned 954,509 shares of the company’s stock, valued at $1,269,496.97. This represents a 0.85% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Thursday, October 15th, Adar1 Capital Management, Llc acquired 984 shares of InMed Pharmaceuticals stock. The stock was purchased at an average price of $1.32 per share, with a total value of $1,298.88.
On Tuesday, October 13th, Adar1 Capital Management, Llc acquired 564 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $750.12.
On Thursday, October 8th, Adar1 Capital Management, Llc acquired 2,256 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, for a total transaction of $3,000.48.
On Wednesday, October 7th, Adar1 Capital Management, Llc bought 3,046 shares of InMed Pharmaceuticals stock. The shares were acquired at an average price of $1.33 per share, for a total transaction of $4,051.18.
On Tuesday, October 6th, Adar1 Capital Management, Llc bought 5,601 shares of InMed Pharmaceuticals stock. The shares were acquired at an average price of $1.33 per share, for a total transaction of $7,449.33.
On Monday, October 5th, Adar1 Capital Management, Llc bought 18,182 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $24,182.06.
On Friday, October 2nd, Adar1 Capital Management, Llc bought 8,307 shares of InMed Pharmaceuticals stock. The stock was acquired at an average cost of $1.33 per share, with a total value of $11,048.31.
On Thursday, October 1st, Adar1 Capital Management, Llc purchased 16,431 shares of InMed Pharmaceuticals stock. The stock was acquired at an average price of $1.33 per share, with a total value of $21,853.23.
On Monday, September 14th, Adar1 Capital Management, Llc purchased 28,505 shares of InMed Pharmaceuticals stock. The stock was acquired at an average price of $1.29 per share, with a total value of $36,771.45.
On Wednesday, September 16th, Adar1 Capital Management, Llc purchased 8,340 shares of InMed Pharmaceuticals stock. The shares were acquired at an average cost of $1.29 per share, for a total transaction of $10,758.60.

InMed Pharmaceuticals Stock Performance

Shares of NASDAQ:INM traded down $0.01 during midday trading on Friday, reaching $1.32. 4,339 shares of the company’s stock traded hands, compared to its average volume of 44,423. InMed Pharmaceuticals Inc. has a one year low of $0.57 and a one year high of $2.33. The company has a market cap of $4.37 million, a price-to-earnings ratio of -0.80 and a beta of 0.93. The stock has a 50 day moving average of $1.38 and a 200 day moving average of $1.30.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last released its quarterly earnings data on Wednesday, September 9th. The company reported ($1.43) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of InMed Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 9th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company presently has an average rating of “Sell”.

View Our Latest Analysis on InMed Pharmaceuticals

Institutional Investors Weigh In On InMed Pharmaceuticals

A hedge fund recently bought a new position in InMed Pharmaceuticals stock. Montanova Capital LLC purchased a new position in InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $155,000. Montanova Capital LLC owned about 3.02% of InMed Pharmaceuticals at the end of the most recent reporting period. 20.12% of the stock is owned by institutional investors.

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery and development of therapies based on rare cannabinoids. The company is developing pharmaceutical candidates intended to address diseases with significant unmet medical needs, using its proprietary IntegraSyn technology to support the production and formulation of cannabinoids.

InMed’s pharmaceutical pipeline has included INM-755, a topical cannabinol-based candidate being investigated for epidermolysis bullosa simplex, a rare genetic skin disorder.